Lung cancer: A review

Overexpression of matrix metalloproteinase-7 (MMP-7) correlates with tumor proliferation, and a poor prognosis in non-small cell lung cancer

“…A surgical resection plays a major role in managing patients with stage I and II NSCLCs, and they are also sometime used for patients with stage III NSCLCs [1]. Various concomitant treatments with chemotherapy and radiotherapy have been assessed to improve the outcome of patients with NSCLCs [2,3].…”

Skin rash and bronchoalveolar histology correlates with clinical benefit in patients treated with gefitinib as a therapy for previously treated advanced or metastatic non-small cell lung cancer

“…Each year 1.2 million people are diagnosed with this disease and more than 1.1 million die as a result of it. Approximately 80% of them have nonsmall cell lung cancer (NSCLC) most often at locally advanced or metastatic stage [1]. Median survival of patient with advanced NSCLC, after progression from first-line therapy is only 4 months.…”

Nanomaterials for Management of Lung Disorders and Drug Delivery

“…The most common histological types of lung cancers include squamous cell carcinoma (30^0%), adenocarcinoma (25-30%), non-small cell lung carcinoma (NSCLC) (10%), and small cell lung carcinoma (15-20%) [11]. Currently, lung cancer is diagnosed by chest radiography, sputum cytology, bronchoscopy, needle biopsy, and following confirmation by histology [12]. For stage I and stage II NSCLC, and some cases of stage III disease, surgery still plays a major role, while stage IIIB is the mostly treated by radiotherapy [12].…”

“…Currently, lung cancer is diagnosed by chest radiography, sputum cytology, bronchoscopy, needle biopsy, and following confirmation by histology [12]. For stage I and stage II NSCLC, and some cases of stage III disease, surgery still plays a major role, while stage IIIB is the mostly treated by radiotherapy [12]. Lung cancers normally metastasize to distant organs including the bones, contralateral lung, liver and brain.…”